A First in Twenty Years for Localized Prostate Cancer: Gene Therapy CAN-2409 Significantly Extends Disease-Free Survival When Added to Radiotherapy
In the phase 3 PrTK03 trial, CAN-2409 plus valaciclovir added to EBRT reduced the risk of recurrence or death in prostate cancer by 30% (HR 0.70; p=0.016).
- 5 DK OKUMA